SAN DIEGO, Dec. 8, 2016 /PRNewswire/ -- Dthera Sciences (OTC: DTHR), a Digital Therapeutics company based in San Diego that is working to improve Quality of Life (QoL) and reduce anxiety in patients with Alzheimer's and Dementia, announced today it has completed the process of becoming a publicly traded company.
"We are very excited to have completed the process of becoming a public company, which is a significant milestone for Dthera Sciences. To our knowledge, we are the first and only publicly-traded Digital Therapeutics company and one of the few targeting the Alzheimer's and Dementia space. We believe that we are ideally positioned to capitalize on both the rise of the Digital Therapeutics market and the expanding need to offer additional solutions in Alzheimer's care," said Edward Cox, CEO.
The Company's lead product is an artificial-intelligence-powered digital health platform that collects photos and audio from family members and creates hyper-personalized video stories which are then sent to the patients. The product is presently in a clinical trial to test its effectiveness as a scalable form of Reminiscence Therapy and the Company expects to announce results in Q1 2017.
Dthera Sciences is presently listed on the OTC market under the symbol DTHR and has a total of 35,853,007 shares outstanding.
About Dthera Sciences:
Dthera Sciences (OTC: DTHR) is a publicly-traded Digital Therapeutics company based in San Diego that is working to improve Quality of Life (QoL) and reduce anxiety in patients with Alzheimer's and Dementia. The company has developed a non-pharmaceutical quality of life therapy for Alzheimer's and Dementia patients, specifically, the Company's lead product is an artificial-intelligence-powered Digital Therapeutic designed to working improve quality of life and reduce anxiety in patients with Alzheimer's and Dementia. For more information please visit www.dthera.com
About Digital Therapeutics:
Digital Therapeutics is a new subsection of digital health that strives to directly deliver a therapy via use or interaction with software technology. The goal of Digital Therapeutics is to mirror an effective treatment and use technology to scale it to a larger patient population, thereby amplifying doctors' and nurses' care, changing patient behavior, and most importantly, reducing cost of care.
About Reminiscence Therapy:
Reminiscence Therapy involves discussing and reviewing recognizable memories, typically by looking at photos, and hearing or discussing the familiar stories related to them. It has been shown to be very effective at reducing anxiety and increasing the overall Quality of Life (QoL) in Alzheimer's and Dementia patients in numerous clinical trials and has been in use for nearly 30 years.
Dthera Sciences Forward-Looking Statement
This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995, regarding the research, development and commercialization of medical products. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. These forward-looking statements are made as of the date of this press release, and the Company assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Readers are urged to read the risk factors set forth in the Company's most recent annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q, and other filings made with the SEC. Copies of these reports are available from the SEC's website at www.sec.gov or without charge from the Company.
For more information: Geno Kostikov, 858-215-6360, firstname.lastname@example.org
SOURCE Dthera Sciences